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Background: Second-line chemotherapy offers advanced non-small 
cell lung cancer (NSCLC) patients a small but signiﬁcant survival 
improvement. Docetaxel is usually administered as a 3-week schedule. 
But it has a high toxicity burden. Therefore, weekly schedule has been 
explored in several trials. In this retrospective study, we compared the 
efﬁcacy and safety of weekly schedule and 3-week schedule docetaxel 
monotherapy as a second-line setting.
Methods: Docetaxel was administered with 75 mg/m2 on day 1 every 3 
week or 37.5 mg/m2 on day 1, 8 every 3 week until disease progression 
or severe toxicity developed.
Results: From October 2003 to March 2006, a total 38 patients 
received docetaxel monotherapy and 37 patients can be evaluated. A 
total 141 cycles were administered and evaluated. The median overall 
survival was 13.3 months (95% Conﬁdence interval; 6.3 ~ 20.3) in 
the weekly schedule and 10.7 months (95% Conﬁdence interval; 8.3 ~ 
13.0) in the 3-week schedule (p=0.41). The median time to progression 
was 3.0 months (95% Conﬁdence interval; 1.9 ~ 4.0) and 2.8 months 
(95% Conﬁdence interval; 1.0 ~ 4.6), respectively (p=0.41). Response 
rate was 16.7% in weekly schedule and 21.1% in the 3-week schedule. 
Major hematologic toxicity was grade 3-4 neutropenia (3-week: 39.2%, 
weekly: 11.9%). Non-hematologic toxicities were similar between the 
two schedules. There were no treatment-related deaths.
Conclusions: Docetaxel weekly schedule is very well tolerable and 
comparable activity with 3-week schedule. Considering efﬁcacy and 
tolerability, it can be alternative schedule of standard treatment as a 
second-line setting. 
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Background: We have previously shown the optimal dose of biweekly 
Gemcitabine and Paclitaxel (GEM/PAC) for the treatment of refractory 
and/or resistant patients with non-small cell lung cancer (NSCLC). 
We conducted a phase II study of this combination chemotherapy to 
evaluate the efﬁcacy and safety of biweekly GEM/PAC in patients with 
NSCLC as a second line chemotherapy after platinum-based chemo-
therapy.
Methods: Patients with measurable tumor who had received one previ-
ous chemotherapy or chemotherapy/radiation regimen were eligible. 
PAC (150mg/m2) was administered ﬁrst over one hour followed by 
GEM (1000mg/m2) over 30minutes and repeated biweekly at least 4 
cycles.
Results: Thirty-one patients were enrolled, median age of 64 yr (range 
39 to 75). Nine were female and twenty-two were male. Stage 3b was 
eleven and Stage 4 was twenty. Thirteen patients had a performance 
status 0, sixteen were 1, and two were 2. Twenty-six patients (84%) 
were received with platinum compound plus Docetaxel regimen. Bi-
weekly GEM/PAC was performed with the median cycles of 5.2 (1-20 
cycles). Partial response observed in seven cases (23%), and stable 
disease was seen in eighteen (58%). Median survival time after GEM/
PAC was seven months. Over grade 3 or 4 hematological toxicity (3%) 
and neurotoxicity (3%) were observed in one patient, respectively. One 
patient who received only one cycle of this chemotherapy developed 
pulmonary toxicities, resulted in fatal respiratory failure.
Conclusions: The biweekly GEM/PAC combination chemotherapy 
was active and well tolerated as a second-line therapy in patients with 
NSCLC. Paclitaxel might be a promising and alternative agent in pa-
tient with previously treated with Docetaxel as ﬁrst line.
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Gemsitabine plus cisplatine therapy in local advanced NSCLC
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In our study, patients who were diagnosed as local advanced NSCLC 
and treated with gemsitabine plus cisplatine (GP) regimen, were evalu-
ated retrospectively. 77 patients ( 72 male and 5 women) who were 
taken more then two cycles of GP chemotherapy and reevaluated after 
chemotherapy is admitted to the study. Patients median age was 65. 
Patiens were evaluated with their stages, responce to the chemotheray 
after 2 and 4 th cycle with WHO responce criteria, time to progression, 
toxicity proﬁles and EQRLC quality of life assesment of 24 patents. 
Median chemotherapy cycle is 3 and 5% complete responce, 39% 
partial responce, 30% stable disease, 26% progressive disease were re-
staged after 2 course of chemotherapy. Median survival is 12,5 mounth 
and time to progression is 5 mounth. Neutropenia and anemia are the 
most common hematological toxicities whilst emezis and allopesia are 
the most common nonhematological toxicities .
P2-273 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
Treatment of elderly 75 years ) with lung cancer. A three-year 
material in clinical practice from Karolinska University Hospital 
- Sweden
Koyi, Hirsh1 Hillerdal, Gunnar2 Brandén, Eva2 
1 Karolinska University Hospital, Solna, Stockholm, SWEDEN 2 Dept 
of Respiratory Medicine and Alergy, Karolinska University Hopsital, 
Stockholm, Sweden 
Introduction: Sixty percent of all neoplasms and two-thirds of all 
deaths due to cancer occur in persons older than 65 years. More than 
50% of patients with lung cancer are older than 65 years and 30% older 
than 70 years. With more persons surviving to older age treatment of 
the elderly with lung cancer has become an important issue.
Material and Method: All patients 75 years or older with lung cancer 
seen at the Department of Respiratory Medicine and Allergy, Karolin-
ska Hospital from 2003 to 2005 were retrospective reviewed. In all, 
334 patients were analyzed. 
Results: The mean age was 80.5 years, 94 (58.1%) were men. 94% of 
the males and 79% of the females were smokers or former smokers. 
246 (73.6%) had PS 0-2. 9.2% had SCLC, 19.9% adenocarcinoma, 
and 6.7% squamous cell carcinoma. 23.9% had clinical lung cancer 
and the others broncheoalveolar cell carcinoma or low differentiated 
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carcinoma. 8.7% underwent radical surgery, 23.7% received chemo-
therapy only, 21.6% radiotherapy against the tumour (thereof stereotac-
tic 5,1%), and 1,5% concomitant chemo-radiotherapy. 6,3% received 
radiotherapy against metastases, and 38% had no therapy. Only 6.3% 
were given second-line chemotherapy. Survival was 219 and 190 days 
for patients 75-80 years and >80 years, respectively. Patients with PS=0 
survived 533 days, those with PS=4 only 20 days. Survival among 
smoker or former smokers and never smokers were 212 and 132 days, 
respectively. Survival among those who received chemotherapy was 
573 days, while for the others it was 181 days.
Conclusions: Signiﬁcant survival among patients given second line 
chemotherapy (p<0.036). Signiﬁcant survival among patients between 
75-80 versus > 80 years old (P<0.032). Treatment of elderly patients 
with lung cancer is feasible if they have a good PS and seems to result 
in prolonged survival.
P2-274 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
Clinical benefits of pemetrexed 500 mg/m2 and 1000 mg/m2 in a 
randomized phase II study for pretreated patients with locally 
advanced or metastatic non-small cell lung cancer (NSCLC)
Kubota, Kaoru1 Tamura, Tomohide1 Yamamoto, Nobuyuki2 Nakagawa, 
Kazuhiko3 Morita, Satoshi4 Nambu, Yoshihiro5 Adachi, Susumu6 
Nishiwaki, Yutaka7 Saijo, Nagahiro7 Fukuoka, Masahiro3 
1 National Cancer Center Hospital, Kashiwa, Japan 2 Shizuoka Cancer 
Center, Shizuoka, Japan 3 Kinki University School of Medicine, Osaka-
sayama, Japan 4 Nagoya University Graduate School of Medicine, 
Nagoya, Japan 5 Eli Lilly and Company, Kobe, Japan 6 Eli Lilly and 
Company, Indianapolis, IN, USA 7 National Cancer Center Hospital 
East, Kashiwa, Japan 
Background: Pemetrexed is a standard treatment for patients with 
locally advanced or metastatic NSCLC who had prior chemotherapy. In 
an international phase III study comparing pemetrexed with docetaxel 
in pretreated patients with NSCLC, pemetrexed showed clinically 
similar efﬁcacy to docetaxel with median survival time (MST) of 8.3 
months. In our Japanese randomized phase II study, the treatment with 
either pemetrexed 500 mg/m2 (Pem 500) and 1000 mg/m2 (Pem 1000) 
showed favorable response rates of 18.5% and 14.8%, respectively. We 
report survival and quality of life (QOL) results of the Japanese phase 
II study.
Methods: Patients with PS 0-2, measurable, stage III/IV NSCLC, who 
had previously received 1 or 2 chemotherapy regimens, were random-
ized to receive either Pem 500 or Pem 1000 on day 1 of a 21-day 
schedule. The primary endpoint was response rate, which has already 
been reported. The secondary endpoints included overall survival and 
QOL. Overall survival was calculated with a Kaplan-Meier method. 
The QOL scores of FACT-L LCS questionnaire were measured at base-
line, before the 2nd and 3rd cycle, and also at 3 months after the regis-
tration to the ﬁrst cycle. Changes from the baseline were calculated.
Results: From October 2004 to October 2005, 244 pts were enrolled at 
28 centers, 226 patients were randomized and treated, and 216 patients 
were evaluated for efﬁcacy. Baseline patient characteristics (Pem 
500/Pem 1000: 108/108 pts) were well balanced between the two arms: 
Males 63%/64%; median age 62/62 years (range: 37-74/26-74); PS 0-1 
94%/94%; stage IV 81%/78%. The median number of treatment cycles 
completed on both arms was 3 (range 1-20+ for Pem 500 and 1-14+ 
for Pem 1000). One year survival rates were 59.2% for Pem 500, and 
53.7% for Pem 1000 with MST of 15.7 and 12.6 months, respectively. 
The QOL scores of LCS questionnaire were obtained from 107/107 
patients (Pem 500/Pem 1000) at baseline, 101/98 patients before the 
2nd cycle, 84/72 patients before the 3rd cycle, and 59/61 patients at the 
last time point (Pem 500/Pem 1000). In both arms, the total LCS scores 
were well sustained from the baseline without aggravation among the 
patients who completed the questionnaire at the last time point. De-
tailed QOL results will be reported at the presentation. 
Conclusions: Pemetrexed is an active agent for pretreated patients with 
NSCLC. Pem 500 showed numerically better response rate and survival 
than Pem 1000. Based on this study, the use of Pem 500 is recommend-
ed for pts with NSCLC in a 2nd or 3rd line setting.
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Background: Doc has clear-cut therapeutic superiority compared to 
best supportive care or ifosfamide/vinorelbine and, as a result, is the 
standard of comparison in the second line setting. In the pre-peme-
trexed era, Gem, in phase II studies, also demonstrated activity in the 
salvage setting with favorable response and survival rates. We therefore 
mounted a phase II trial pairing these two agents in pts with progressive 
disease after prior platinum-based therapy.
Materials and Methods: Pts with advanced NSCLC and ECOG PS 
0-1 progressing either during or after prior platinum-based therapy 
received Doc 40 mg/m2 days 1 and 8, in combination with Gem 800 
mg/m2 days 1 and 8. In the absence of dose limiting myelosuppression 
or other gr ≥3 toxicities, Gem dose was escalated on an intra-patient 
basis to 1000 mg/m2 days 1 and 8. Pts continued treatment until disease 
progression or unacceptable toxicity.
Results: 35 pts were enrolled: 20 (57%) were male; 69 % were ECOG 
PS 1; 57% had received prior XRT. Median age was 61 (range 30-79). 
Median time from initial diagnosis to enrollment was 12.4 mos. 170 
cycles total were administered (median 4, range 1-16). 35% received 
≥ 6 cycles. Overall response rate was 24% (95% CI 12-39%). Median 
event free survival (EFS) was 5.7 mos; median overall survival 12.5 
mos. 1 year survival rate was 51%, and 2 year survival rate 20%. Those 
enrolled within 12 mos of initial diagnosis had poorer EFS compared 
to those after 12 mos (log rank p=0.04). There were no treatment-re-
lated deaths. Typical grade ≥ 3 toxicities included neutropenia (58%), 
diarrhea (6%), pneumonitis (9%), and dermatitis (9%), including nail 
changes.
Conclusion: Combination docetaxel and gemcitabine administered 
on a weekly basis, days 1 and 8 every 3 weeks in good performance 
NSCLC patients with PD after/during platinum-based therapy appears 
encouraging, and presents a viable option in this population. Proof of 
beneﬁt requires phase III testing. 
